Rectal cancer.
Rectal cancer is an important tumour from an epidemiological point of view and represents the benchmark for an optimal use of integrated treatments (surgery, radiotherapy and chemotherapy) in the oncological practice. The conventional use of total mesorectal excision and the integration with radiochemotherapy, better if preoperatively, are now able to increase survival, to decrease the occurrence of pelvic recurrence and to ameliorate the quality of life of patients. Updated recommendations for the management of these patients are here reported.
Zampino
Maria Giulia
MG
Medical Care Unit, European Institute of Oncology, Milan, Italy. maria.zampino@ieo.it
Labianca
Roberto
R
Beretta
Giordano D
GD
Magni
Elena
E
Gatta
Gemma
G
Leonardi
Maria Cristina
MC
Chiappa
Antonio
A
Biffi
Roberto
R
de Braud
Filippo
F
Wils
Jacques
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D015994:Incidence; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents